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Abstract Pleckstrin homology (PH) domains are discrete 
structural modules present in numerous proteins involved in 
signal transduction processes. In the case of the P-adrenergic 
receptor kinase (PARK), PH domain-mediated binding of two 
ligands, the Py subunits of heterotrimeric G proteins (GPY) and 
phosphatidylinositol 4,5-bisphosphate (PIP2), has been shown to 
be required for the kinase function. In this study, the ability of 
GPy and PIP2 to affect membrane localization of PARK is used 
to define the ligand binding characteristics of the PARK PH 
domain. The binding of these ligands to the PH domain of the 
intact kinase is shown to be cooperative, GPY increasing the 
affinity of the PH domain for PIP2. Notably, although PIP2-
dependent membrane association of PARK is observed at high 
concentrations of this lipid, in the absence of GPY, no receptor 
phosphorylation is observed. Peptides derived from the receptor 
intracellular loop inhibit the receptor phosphorylation without 
affecting the membrane translocation of the kinase complex, 
suggesting that PARK activity does not necessarily correlate with 
the amount of PARK associated with the membrane. These 
results point to a distinct role for each PH domain ligand in 
pARK-mediated receptor phosphorylation. Strikingly, the ligand 
binding characteristics of the isolated PARK PH domain fused to 
glutathione 5-transferase are very different from those of the PH 
domain of the intact kinase. Thus, in contrast to the native 
protein, the isolated PH domain binds GPY and PIP2 
independently and with no apparent cooperativity. That protein 
environment plays an important role in determining the ligand 
binding characteristics of a particular PH domain highlights the 
potential risks of inferring mechanisms from studies of isolated 
PH domains. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Pleckstrin homology (PH) domains are approximately 100— 
120 amino acid regions of sequence homology found in nu-
merous proteins involved in various signaling pathways [1-7]. 
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Several potential ligands for PH domains have been identified 
including the Py subunits of heterotrimeric G proteins (GPy) 
[8-13] or GP-like WD40 motif-containing proteins [14,15], 
phosphatidylinositol 4,5-bisphosphate (PIP2) [16-18], inositol 
1,4,5-trisphosphate (IP3) [19-21], and protein kinase C (PKC) 
[22,23]. Although the physiological relevance of the binding of 
these ligands remains to be elucidated, the PH domain has 
been proposed to play a role in membrane recruitment of PH 
domain-containing proteins, thus targeting them to appropri-
ate cellular compartments or enabling them to interact with 
other components of the signal transduction pathway. 
The ligand binding characteristics of one PH domain, that 
of the P-adrenergic receptor kinase (pARK), have recently 
been defined using purified proteins in a reconstituted system. 
The PARK, a member of the G protein-coupled receptor kin-
ase (GRK) family, phosphorylates and thus desensitizes ago-
nist-occupied G protein-coupled receptors [24-26]. The car-
boxyl-terminal PH domain of the PARK has been proposed 
to play an essential role in mediating this process, since in 
vitro, the simultaneous presence of two PH domain-binding 
ligands (GPy and PIP2) is required for the membrane associ-
ation of this kinase and p2-adrenergic receptor (PAR) or mus-
carinic acetylcholine receptor phosphorylation [27-29]. 
Three-dimensional structural analyses of several PH do-
mains (i.e. pleckstrin [30], spectrin [31], dynamin [32-34], 
and phospholipase C8 [35]) reveal a common structure, a P-
barrel of seven antiparallel P-sheets and a carboxyl-terminal 
amphiphilic a-helix. Interestingly, the phospholipid has been 
demonstrated to bind a cleft of the P-barrel at the amino-
terminus of this domain [16,18] while studies with mutant 
PARK constructs suggest a GPy binding site encompassing 
the carboxyl-terminal a-helix [8,9,36]. Thus the coordinated 
binding of two PH domain ligands, one at the carboxyl-
and one at the amino-terminus of the PARK PH domain, 
seems to be essential for kinase localization and function. 
Whether membrane localization mediated by the coordinated 
binding of multiple ligands is a feature common to all PH 
domains remains to be further investigated. 
Previous studies examining the role of the PARK PH do-
main have focused predominantly on the functional conse-
quences of GPY and PIP2 binding [28,29]. Directly examined 
herein are the roles played by these ligands in mediating mem-
brane association of the PARK, using either the intact kinase 
or alternatively a PARK PH domain-containing fusion pro-
tein. The aim of this study is to address the following specific 
questions, (i) Can the synergistic enhancement of receptor 
phosphorylation by PIP2 and GPy indeed be accounted for 
by the cooperative binding of PIP2 and GPy to the PH do-
main and subsequent membrane translocation? (ii) If so, does 
the isolated PH domain reflect the function of the PH domain 
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in the intact P A R K ? (iii) Is the P H domain-mediated mem-
brane localization of P A R K sufficient to account for the en-
hanced phosphorylation of the receptor? The results highlight 
the importance of assessing P H domain function in the con-
text of an intact protein and suggest that GPy and PIP2 play 
coordinated but distinct roles in P A R K membrane transloca-
tion and pARK-mediated receptor phosphorylation. 
2. Materials and methods 
2.1. Materials 
Bovine BARK was purified from recombinant baculovirus-infected 
Sf9 cells and GBy subunits were purified from bovine brain as pre-
viously described [37,38]. Glutathione S-transferase (GST) fusion pro-
teins derived from the BARK1 carboxyl-terminus (GST-B1CT) was 
expressed in and purified from Escherichia coli strain NM522 [8,9]. 
GST fusion protein derived from the third loop of human p2-adren-
ergic receptor (pAR-31) (residues 219-276) was similarly prepared. 
Synthetic peptides were designed from the third loop of PAR: peptide 
PI (residues 219-247 of the pAR) and peptide P2 (residues 248-278 of 
the PAR). Purified lipids and partially dephosphorylated casein were 
obtained from Sigma. 
2.2. Purification and reconstitution of the pAR 
The human pAR was expressed, purified, and reconstituted into 
vesicles of defined lipid composition as described previously [28,39]. 
Briefly, baculovirus-infected Sf9 cells were lysed, a membrane fraction 
prepared and pAR solubilized with 0.25% w/v w-dodecyl p-D-malto-
side. The PAR was subsequently purified by aifinity chromatography 
on an alprenolol-Sepharose column [39]. Purified receptor was recon-
stituted into vesicles of defined lipid composition and receptor con-
centration determined as described in [28,39]. 
2.3. PARK-mediated PAR phosphorylation 
The PAR (3.0 pmol) reconstituted in PC vesicles containing defined 
concentrations of PIP2 (described in the text and figure legends) was 
incubated with PARK (6.0 pmol) in either the presence or absence of 
GPy (6.0 pmol). Reactions were performed as described in Pitcher et 
al. [28], with the exception that the final reaction volume was 30 ul. 
The final lipid concentration was 1.7 mg/ml in all assays. Thus, the 
amount of PIP2 in vesicles composed of 95% PC, 5% PIP2, for exam-
ple, is 2.5 ug. All assays contained 50 uM (-)-isoproterenol. Reac-
tions were incubated at 30°C and stopped after 15 min by addition of 
an equal volume of SDS sample loading buffer [28]. Reactions were 
subsequently subjected to electrophoresis on 10% SDS-polyacrylamide 
gels. Dried gels were quantified by Phosphorimager analysis and ex-
posed to film. 
2.4. Lipid vesicle binding assay 
The ability of PARK or the GST-B1CT to bind to PC vesicles 
containing various concentrations of PIP2 was examined using the 
centrifugation assay described in [28,36]. Briefly, lipid vesicles of de-
fined composition with or without PAR (3 pmol in 30 ul scale) were 
incubated with purified PARK (6.0 pmol) or the GST-B1CT fusion 
protein (6.0 pmol) in either the presence or absence of GPy (6.0-12.0 
pmol) for 10 min at room temperature and an additional 5 min on ice. 
Following centrifugation, 100000 rpm (TL-100 rotor) for 15 min at 
4°C, the distribution of the PARK or the GPy between the super-
natant and pellet fractions was determined by Western blot analysis 
(ECL, Amersham Corp.) using anti-pARKct antibodies [28] or anti-
bodies to the P subunit of GPy (DuPont NEN) at a dilution of 1:1000. 
Blots were subsequently quantified by densitometry. 
3. Results and discussion 
The simultaneous binding of GPy and PIP2 to the P H do-
main of the p A R K has been shown to enhance pARK-medi-
ated PAR phosphorylation by facilitating the membrane local-
ization of this kinase [28]. This GPy- and PIP2-dependent 
association of the P A R K with lipid vesicles has been utilized 
in this study to examine the ligand binding characteristics of 
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Fig. 1. PIP2- and GPy-dependent membrane association of GST-
B1CT (A) and PARK (B). Large unilamellar vesicles composed of 
PC containing the indicated concentrations of PIP2 were prepared 
as described in Section 2. Following incubation with either the in-
tact PARK or the GST-B1CT vesicles (±Gpy) were recovered by 
centrifugation and the distribution of the PARK proteins between 
the supernatant and pellet fractions determined by Western blot 
analysis (see Section 2). The results shown are expressed as the per-
cent PARK or GST-B1CT associated with the pellet and represent 
the means ± S.E.M. of three separate determinations. Incubations 
were performed in the absence of Gpy (o), in the presence of an 
equimolar ratio of GPy:PARK protein (200 nM GPy) (•), or in the 
presence of 2-fold molar excess of Gpy: PARK protein (400 nM 
GPy) ( A ) . A representative Western blot showing the distribution of 
the PARK or the GST-B1CT between the supernatant (s) and pellet 
(p) fractions at various PIP2 concentrations is also shown. The as-
sociation of GPy with vesicles regardless of lipid composition was 
assessed by Western blot analysis using the anti-GP antibodies (data 
not shown). 
the p A R K P H domain. Essentially all GPy were found to 
associate with vesicles of any lipid compositions utilized in 
this study according to the Western blot analysis. As shown 
in Fig. IB, the simultaneous presence of both P H domain 
ligands is required for effective membrane localization of the 
PARK. Addit ion of GPy alone or low concentrations of PIP2 
(5% or less) fail to promote membrane association of the 
kinase. Some PIP2-mediated membrane association of the 
P A R K is observed at high concentrations of this lipid (10% 
or higher) in the absence of GPy, however, the coordinated 
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Fig. 2. PIP2- and GBy-dependent membrane association of PARK 
in the presence of PAR. A: Membrane association of the PARK 
with PAR-containing vesicles. Purified pAR reconstituted in vesicles 
containing PC and PIP2 at the concentrations indicated were incu-
bated with purified PARK, the vesicles were recovered by centrifu-
gation, and the distribution of the kinase determined as previously 
described (see Section 2). The results shown are expressed as the 
percentage of the pARK associated with the vesicle (pellet) frac-
tion ±S.E.M. of three separate determinations. Incubations were 
performed in the absence of Gpy (o), or the presence of an equimo-
lar ratio of GPy:pARK (200 nM GPy) (•). B: A representative 
Western blot showing the distribution of the PARK (±GPy) be-
tween the supernatant (s) and pellet (p) fractions at various PIP2 
concentrations. 
presence of both G(3y and PIP2 dramatically increases the 
amount of membrane-associated PARK and the apparent af-
finity of PARK for PIP2. The apparent EC50 for PIP2 de-
creases from, respectively, > 20% to approximately 5% PIP2 
in the absence and presence of 200 nM GPy (Fig. IB). Binding 
of GPy appears to increase the affinity of the PH domain of 
the pARK for PIP2. From these experiments, it cannot be 
clearly distinguished from the possibility that PIP2 functions 
to increase the affinity of PARK for GPy. Nonetheless, direct 
assessment of the GPy- and PIP2-mediated membrane associ-
ation of the PARK provides a clear demonstration of the 
coordinated binding of these two ligands to the PARK PH 
domain. Previous studies using wild type or mutated PH do-
main fusion proteins demonstrated that the PH domain of the 
PARK is the sole region of the enzyme that interacts with 
both GPy and PIP2 [28,36], excluding the possibility that the 
cooperativity is due to binding of the ligands to regions other 
than the PH domain. 
Interestingly, comparison of the ligand binding properties 
of the pARK PH domain in the intact enzyme (Fig. IB) with 
the ligand binding properties of the PARK PH domain in a 
GST fusion protein (Fig. 1A) reveals striking differences. The 
PH domain of the PARK when expressed as a GST fusion 
protein (GST-B1CT) binds both GPY and PIP2 independently 
and without apparent cooperativity (Fig. 1A). Thus in the 
absence of Gpy, 3% PIP2 is sufficient to promote complete 
membrane association of the GST-B1CT (Fig. 1A). Similarly, 
membrane association of the GST-B1CT was observed in the 
absence of PIP2 upon addition of GPy (Fig. 1 A). The amount 
of membrane associated fusion protein increases from 
30 ± 10% to 55 ± 7% on addition of 200 nM GPy (Fig. 1 A). 
These results are consistent with previous studies demonstrat-
ing either PIP2 [16,36] or GPy [8,36] binding to PH domain-
containing fusion proteins. The binding of GST-B1CT to the 
vesicles in the absence of PIP2 and Gpy (30 ± 10%) turned out 
to be a non-specific binding that could be removed by gel 
filtration column [40]. The ability of the GST-B1CT to bind 
either GPy or PIP2 clearly distinguishes this protein from the 
intact PARK. The markedly different binding characteristics 
of the PARK PH domain in either the intact enzyme or the 
GST fusion protein highlight the difficulties of inferring PH 
domain function in the absence of the appropriate protein 
context, although the possibility that it is due to the difference 
in the way of preparation (i.e. Sf9 cells or E. coli cells) cannot 
be excluded. These results reveal an important, and poten-
tially general, caveat: that the behavior of an isolated PH 
domain does not necessarily reflect the function of that 
same PH domain in the context of an intact protein. The 
dose-dependent membrane association of PARK by PIP2 
and GPy, measured here using direct binding studies, suggests 
that the synergistic enhancement of receptor phosphorylation 
reported by Pitcher et al. [28] and DebBurman et al. [29] can 
indeed be accounted for by the GPy/PIP2-mediated membrane 
association of the pARK. 
To investigate a potential role for the receptor substrate in 
modulating PARK distribution, binding assays were per-
formed using lipid vesicles containing purified PAR and var-
ious concentrations of PIP2 (Fig. 2). Under these conditions, 
the GPy- and PIP2-dependent membrane association of the 
pARK is somewhat enhanced but not significantly as com-
pared with that obtained in the absence of receptor (compare 
Fig. lBFig. 2A). Thus the presence of the receptor substrate 
in either the agonist-occupied (data not shown) or -unoccu-
pied (Fig. 2) conformations has itself no significant effect on 
PARK distribution except at 1% PIP2. These results contra-
dict previous studies in which heat inactivation of receptor 
impaired translocation of the pARK/GPy complex, suggesting 
that the presence of receptor enhances pARK translocation in 
the presence of GPy [27]. The reconstituted vesicles in this 
study, however, consist of more defined lipid composition, 
not like the crude phospholipids or rod outer segment utilized 
before. Therefore, it may not be surprising to see less effect of 
receptor on PARK translocation under these conditions. 
Interestingly, although significant membrane association of 
the PARK is observed at high PIP2 concentrations in the 
absence of GPy (Fig. lBFig. 2), no agonist-dependent receptor 
Fig. 3. PIP2-dependent PAR phosphorylation by PARK in the pres-
ence or absence of GPy. Autoradiograph showing GPy-dependent 
pARK-mediated PAR phosphorylation at various concentrations of 
PIP2. Phosphorylations were performed as described in Section 2. A 
representative autoradiogram is shown. Similar results were obtained 
in four separate experiments. 
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Fig. 4. Effect of a pAR third loop fusion protein and peptides on 
GPy/PIP2-mediated PARK membrane association and receptor 
phosphorylation. A: Inhibition of GPy/PIP2-mediated pARK trans-
location to vesicles composed of 95% PC and 5% PIP2 by fusion 
proteins (5 uM) and synthetic peptides (1 mM). Experiments were 
performed as described in Section 2 and results are expressed as 
percent pARK associated with the vesicle pellets under the condi-
tions indicated. The amount of PARK present in the pellet fraction 
in the presence of 5% PIP2 and 200 nM GPy and in the absence of 
added fusion protein or peptide is taken as 100%. The results repre-
sent the means ±S.E.M. of three separate determinations. B: Inhibi-
tion of GPy/PIP2-dependent PARK-mediated PAR phosphorylation 
by fusion proteins (5 uM) and synthetic peptides (1 mM). The re-
sults are expressed as percent PARK activity where the incorpora-
tion of 32P into the PAR in the absence of peptide additions is tak-
en as 100%. The percent PARK activity is shown as means ± S.E.M. 
of three separate determinations. GST, glutathione 5-transferase; 
PAR-31, PAR fusion protein encoding residues 219-276 of the PAR 
(the third intracellular loop); PI, peptide encoding residues 219-247 
of the PAR; P2, peptide encoding residues 248-273 of the PAR. 
phosphorylation is observed under these conditions (Fig. 3). 
Thus, conditions which result in the membrane association of 
equivalent amounts of the PARK (i.e. 5% PIP2/200 nM GPy 
or ~ 1 5 % PIP2 alone) lead to distinct functional consequen-
ces, receptor phosphorylation being observed only in the pres-
ence of GPy. Regardless of the presence of GPy and PIP2, the 
phosphorylation is always agonist-dependent. These results 
suggest that PH domain-mediated localization of the PARK 
to the membrane is insufficient to account for the dramatic 
enhancement of PARK-mediated PAR phosphorylation ob-
served in the presence of GPy and PIP2. pARK-catalyzed 
phosphorylation of a soluble substrate (casein) was unaffected 
when assayed under these conditions in either the presence or 
absence of GPy (data not shown) [28]. Thus, no inhibition was 
observed at the concentrations of PIP2 used in this study, 
demonstrating that these effects on receptor phosphorylation 
are not the results of an inhibitory effect of PIP2 on PARK 
activity. The binding of GPy to the PARK appears to play an 
important role in specifically targeting the enzyme complex to 
its receptor substrate. Requirement of GPy for receptor phos-
phorylation is consistent with the paper by Pitcher et al. [28]. 
The apparent difference from previous studies that observed 
phosphorylation in the absence of Gpy has been shown to be 
due to the crude phospholipid vesicles utilized in those studies 
[28]. 
In an attempt to distinguish PH domain-mediated mem-
brane localization of the PARK from PH domain-mediated 
receptor targeting, the effects of various fusion proteins or 
peptides on PARK membrane association (Fig. 4A) or 
PARK-mediated PAR phosphorylation (Fig. 4B) were inves-
tigated. Peptides derived from various intracellular loops of 
the PAR have previously been demonstrated to inhibit 
PARK-mediated PAR phosphorylation in vitro [41]. These 
peptides, which are not pARK substrates, block formation 
of the pARK/receptor substrate complex. A GST fusion pro-
tein encompassing the third loop of the PAR (pAR-31), to-
gether with two synthetic peptides derived from the PAR third 
loop (PI and P2), were tested for their ability to block GPy-
and PIP2-mediated membrane association. The PAR-31 fusion 
protein (5 uM), peptide PI (1 mM) and peptide P2 (1 mM) 
inhibited pARK-mediated pAR phosphorylation as previ-
ously reported [28,41] (Fig. 4B) while having no significant 
effect on the Gpy- and PIP2-dependent membrane association 
of this kinase (Fig. 4A). Neither the PAR-31, PI or P2 inhib-
ited PARK-mediated phosphorylation of casein (data not 
shown), indicating that these peptides specifically inhibit in-
teraction of the pARK with its receptor substrate. The ability 
to selectively inhibit receptor targeting of the PARK without 
affecting the membrane localization of this kinase demon-
strates the separate contributions of these two processes to 
the PH domain-mediated enhancement of PARK activity. 
Also demonstrated is that pARK activity does not necessarily 
correlate with the amount of PARK associated with the mem-
brane. In contrast to the PAR peptides, the GST-B1CT (PH 
domain fusion protein) inhibits both membrane association of 
the pARK and pARK-mediated receptor phosphorylation, 
demonstrating that PH domain is crucial for both membrane 
association and receptor phosphorylation (Fig. 4). That this 
inhibition was dependent on the presence of the PARK PH 
domain, and thus reflects the ability of this protein to com-
petitively inhibit the binding of GPy and PIP2 to the PARK, 
is demonstrated by the inability of GST alone to inhibit either 
of these processes. Therefore, although PIP2 binding to the 
PH domain is sufficient for PARK to be translocated to the 
membrane, GPy/PIP2/pARK complex formation is necessary 
to recognize the receptor substrate for phosphorylation. 
Two recent papers studying the effect of PIP2 addition on 
the PARK concluded that this lipid directly inhibits PARK 
activity [42,43]. These results apparently contradict those pre-
sented in this and a previous paper [28], in which PIP2 is 
shown to be required for GPy-dependent PARK-mediated re-
ceptor phosphorylation. This apparent contradiction turned 
out to arise as a consequence of the differences in PIP2 con-
centration and of the experimental differences in vesicle prep-
arations [44]. In contrast to the receptor-containing vesicles 
composed of a mixture of PC and PIP2 [28,44], when PIP2 
vesicles were exogenously added into the receptor-reconsti-
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tuted vesicles, it appeared to sequester the PH domain from 
the receptor environment resulting in inhibition of the phos-
phorylation [42,43]. Most recently, DebBurman et al. [29] 
demonstrated that at low concentrations PIP2 activated 
BARK via an interaction with the BARK PH domain, while 
at high concentrations PIP2 inhibited BARK activity appar-
ently via another mechanism. 
The concentrations of PIP2 required for efficient membrane 
association of the BARK in this in vitro assay is still some-
what higher than those found physiologically (i.e. range be-
tween 0.25% and 1.0% of the total plasma membrane [45]), 
however the simplified lipid environment was required to ex-
amine how the two PH domain ligands interact with the 
BARK PH domain. Interestingly, the results obtained using 
small unilamellar vesicles, which were prepared by simple son-
ication, appeared to be quite different from those obtained in 
this study in which larger unilamellar vesicles were utilized. 
Thus, the translocation of BARK to the sonicated vesicles was 
observed with EC50 0.6% ± 0.1 of PIP2 in the absence of GBy 
and 0.07%o ±0.02 of PIP2 in the presence of an equimolar 
ratio of GBy:BARK (data not shown). The binding appears 
to be cooperative in a fashion similar to the results obtained 
in Fig. IB. Previously, the binding of GST-B1CT to PIP2 was 
observed at 1% PIP2 vesicles [16], consistent with these re-
sults. The EC50 values for the reconstituted vesicles in this 
study are higher, but these vesicles reflect a more physiological 
environment. Nonetheless, in the future, the in vivo signifi-
cance of PIP2 binding to the BARK PH domain must be 
examined by determining the in vivo function of modified 
BARK in which PIP2-binding sites are mutated, since the 
model membrane utilized here represents an oversimplification 
of the in vivo situation in that it lacks other lipids such as 
phosphatidylserine that have previously been shown to en-
hance BARK activity [29]. Thus it remains to be determined 
whether a more complex lipid environment influences the af-
finity of the BARK PH domain for PIP2. 
The data presented in this paper serve to elucidate the li-
gand-binding characteristics of the PH domain of BARK. 
Binding of GBy and PIP2 to the PH domain of this protein 
occurs cooperatively, with GBy binding increasing the affinity 
for PIP2. Furthermore, the PH domain-mediated binding of 
GBy and PIP2 serves two coordinated but distinct functions: 
localization of the BARK to the membrane and additionally 
targeting of this complex to its receptor substrate. PH do-
main-mediated membrane association alone appears insuffi-
cient to account for the dramatically enhanced BARK-medi-
ated BAR phosphorylation observed upon addition of GBy 
and PIP2. It remains to be elucidated whether a general fea-
ture of PH domains is the binding of multiple ligands. If this 
is indeed the case then the BARK PH domain may provide a 
general paradigm in which one, or multiple, ligands dictate 
the membrane localization of the PH domain-containing pro-
tein while a specific ligand localizes these proteins to their 
appropriate cellular targets. 
Comparison of the ligand-binding characteristics of the PH 
domain of the BARK in two different protein environments, 
the intact kinase and a GST fusion protein, reveal important 
and significant differences. The independent binding of GBy 
and PIP2 to the BARK fusion protein contrasts sharply with 
the cooperative binding of these PH domain ligands to the 
intact enzyme. That PH domain ligand-binding characteristics 
depend on protein context represents an important and poten-
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tially general caveat to be considered when investigating the 
functional characteristics of isolated PH domains. 
The following novel conclusions emerge from this study. 
First, the binding of GBy and PIP2 to the PH domain of 
BARK is cooperative, GBy increasing the affinity of the PH 
domain for PIP2, accounting for the enhanced receptor phos-
phorylation by these ligands. Second, the markedly different 
binding characteristics of the PH domain in the intact enzyme 
or the isolated PH domain highlight the potential difficulties 
of inferring PH domain function in the absence of the appro-
priate protein context. Third, the PH domain-mediated mem-
brane localization of the BARK by PIP2 alone is insufficient 
to account for the enhanced phosphorylation of the receptor 
substrate. Finally, the PH domain-mediated binding of PIP2 
and GBy serves two coordinated but distinct functions: local-
ization of the BARK to the membrane and targeting of this 
complex to its receptor substrate. The in vivo significance of 
PIP2 or GBy binding to the BARK PH domain remains to be 
elucidated. 
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